Main Industry
Biotechnology
Main Product/Service
1. Ronkyla
2. Ronlytic™™
3. Ronkyla® Gel
4. Ronkyla® Plus
2. Ronlytic™™
3. Ronkyla® Gel
4. Ronkyla® Plus
Founded Year
2018
Unified Business No.
55797608
Status
Active
Number of Employees
0
Total Paid-in
Capital
16,687,500 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
was founded in 2018, aimed to mark breakthroughs, newer, more effective, and safter products.
The initial three products will provide solutions for localized fat reduction in the human body. In addition to the benefits of safety, quality, and convenience, these products are also patented innovative medications. The first product, "Ronkyla Injection" has already received approval from the Taiwan Ministry of Health and Welfare and is successfully on the market.
In the subsequent phase of new product development, the focus will be on further improving the existing products, leading to "Ronkyla Gel" and "Ronkyla Plus" These products aim to achieve better therapeutic effects with fewer side effects, offering healthcare professionals better choices. This allows patients to undergo treatment without undue burden, build self-confidence, and pursue a better quality of life.
The initial three products will provide solutions for localized fat reduction in the human body. In addition to the benefits of safety, quality, and convenience, these products are also patented innovative medications. The first product, "Ronkyla Injection" has already received approval from the Taiwan Ministry of Health and Welfare and is successfully on the market.
In the subsequent phase of new product development, the focus will be on further improving the existing products, leading to "Ronkyla Gel" and "Ronkyla Plus" These products aim to achieve better therapeutic effects with fewer side effects, offering healthcare professionals better choices. This allows patients to undergo treatment without undue burden, build self-confidence, and pursue a better quality of life.
